



Q1/2017 RESULTS



R&D Highlights


46 pharmaceutical NMEs and vaccine candidates in clinical development

13 NMEs and vaccine candidates in Phase III or submitted to regulatory authorities


2 NMEs entered Phase II

1 NME entered Phase I

Net Company Sales & Business EPS



Sales by Global Business Units



Sales by Geography

